Vatinoxan alleviates the adverse effects of alpha2-adrenoceptor agonist drugs (A2D). A2D drugs are sedative and pre-anaesthetic pharmaceuticals very commonly used in veterinary medicine. Vatinoxan functions by blocking the action of A2Ds in the central nervous system, as it cannot effectively cross the blood-brain barrier. We have shown that it mitigates numerous adverse effects associated with the use of A2Ds, such as cardiovascular depression, hyperglycaemia and diuresis. Vatinoxan has been actively studied in several animal species. Today, it has marketing authorisation in Europe and the United States in a sedative combination for dogs.
Our research focuses on new indications for vatinoxan in many animal species that are central to veterinary medicine.
Nausea is a well-known phenomenon in animals. But do species that are unable to vomit experience nausea and related loss of appetite? We believe so.
In 2025, our research group launched a project aimed at identifying mechanisms of nausea in ruminants and horses. Our research is the first step towards finding pharmacological solutions for treating nausea and lack of appetite in large, non-vomiting species.